-
Global $200 Billion Opportunity for Nanoparticle Drug Delivery Market by 2024 - Size, Current Trends, and Dynamics
20 Apr 2018 15:38 GMT
… increasing demand for effective treatment methods to provide for … the potential of nanoparticle drug delivery segment.
Advancement in … Company
14.6 Fenofibrate (Lipanthyl & TriCor)
14. … 15.2 Access Pharmaceuticals
15.3 Alnylam Pharmaceuticals
15.4 …
-
US$ 200 Billion Opportunity: Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2024
20 Apr 2018 07:10 GMT
… demand for effective treatment methods to provide … Drug: 231 Drugs
Drugs In & Above Phase II Trials: 33 Drugs
Marketed Nanoparticle Drugs: 13 Drugs …
14.6 Fenofibrate (Lipanthyl & TriCor)
… 2 Access Pharmaceuticals
15.3 Alnylam Pharmaceuticals
15. …
-
are more risky than beneficial, the full list
10 Jan 2023 11:38 GMT
… the French medical journal Prescrire specialized in diseases, medical techniques, drugs. The … , there are 107 drugs to avoid.
Medicines used in hematology and … Ciprofibrate (Lipanor or other)
Fenofibrate (Lipanthyl or other)
Dronedarone (Multiq)
Ivabradina …
-
Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study
16 Nov 2024 11:48 GMT
… from both patients and doctors.
Study Design
The … fenofibrate tablets once daily (Lipanthyl® Supra 160 mg, Mina … demonstrated that lipid lowering drugs, statins, taken at high doses … before and after treatment. Therefore, future trials may include placebo …
-
Abbott Laboratories: A Lesser Johnson & Johnson?
04 Aug 2022 22:42 GMT
… via medical devices, diagnostics equipment, specialized nutrition and pharmaceuticals, and … operational. Abbott's pharmaceutical products relate mainly to … (pinaverium bromide), Duspatal (mebeverine), Lipanthyl and Tricor (fenofibrate), and Synthroid …
-
OxThera Announces the Appointment of Dr Alain Munoz to its Board of Directors
12 Jun 2018 16:08 GMT
… Drug Agency. Alain has over 25 years' experience in the pharmaceutical … obtained world-wide (Adenocard®, Plavix®, Lipanthyl®/Tricor™, Esclim®, Ikervis®) Alain … .
OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH …
About
© 1995-2025